Lee F I, Hardman M, Jaderberg M E
Department of Gastroenterology, Victoria Hospital, Blackpool, Lancashire.
Gut. 1991 Feb;32(2):151-3. doi: 10.1136/gut.32.2.151.
Two hundred patients received either ranitidine 150 mg or 300 mg at night for 18 months to prevent duodenal ulcer relapse. Recurrence rates were lower in patients receiving the higher dose of ranitidine (3.1% v 9.7%, p = 0.78; 6.5% v 16.7%, p = 0.037; and 8.9% v 17.0%, p = 0.121 at six, 12, and 18 months respectively). In patients receiving ranitidine 150 mg, recurrences were significantly more common in smokers than non-smokers after 12 and 18 months, while in patients receiving ranitidine 300 mg recurrence rates were similar in smokers and non-smokers. Ranitidine 300 mg at night abolishes the adverse effect of smoking observed during maintenance treatment with ranitidine 150 mg at night and may therefore be an appropriate maintenance dose for smokers who relapse during standard dose maintenance treatment.
200例患者在夜间服用150毫克或300毫克雷尼替丁，持续18个月以预防十二指肠溃疡复发。接受高剂量雷尼替丁的患者复发率较低（分别在6个月、12个月和18个月时，复发率为3.1%对9.7%，p = 0.78；6.5%对16.7%，p = 0.037；8.9%对17.0%，p = 0.121）。在接受150毫克雷尼替丁的患者中，12个月和18个月后，吸烟者的复发明显比非吸烟者更常见，而在接受300毫克雷尼替丁的患者中，吸烟者和非吸烟者的复发率相似。夜间服用300毫克雷尼替丁消除了夜间服用150毫克雷尼替丁维持治疗期间观察到的吸烟的不良影响，因此对于在标准剂量维持治疗期间复发的吸烟者来说，可能是一个合适的维持剂量。
